IEX
IDEX Corporation177.19
-1.50-0.84%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
No industrial inflection; HST backlog surges
Q&A largely reaffirmed prepared remarks, but drilled down on absent industrial demand inflection—despite PMI above 50, rapid replenishment orders stayed flat through January. HST's record $493M orders built $100M YoY backlog, broad-based beyond data centers (nearly half direct), with January momentum intact and low capex needs. New CFO Sean Gillen pegged buybacks at $75M quarterly base, prioritizing bolt-ons over divestitures. Life sciences holds low-single digits amid NIH funding questions. No inflection yet. Management stays confident on HST expansion, eyes industrial snapback velocity.
Key Stats
Market Cap
13.34BP/E (TTM)
27.99Basic EPS (TTM)
6.33Dividend Yield
0.02%Recent Filings
10-K
FY2025 results
IDEX posted record FY2025 net sales of $3.46B, up 6% y/y with 1% organic growth as price gains across segments offset volume softness in FMT and FSDP. HST surged 15% to $1.50B on 4% organic gains from data center/semiconductor demand, while FMT edged down 1% and FSDP held flat; adjusted EBITDA margins held steady at 26.8%. Q4 saw $248M share repurchases and $213M dividends amid $681M operating cash flow. Strong cash generation funds bolt-ons. Yet supply chain snarls persist.
8-K
Exec position eliminated
IDEX Corporation eliminated the position of Roopa Unnikrishnan, Senior Vice President and Chief Strategy and Innovation Officer, effective February 28, 2026, following notification on February 4. The company expects a separation agreement per her letter agreement for termination without cause, as detailed in the March 26, 2025 proxy statement. Position axed. No further impacts disclosed.
8-K
Q4 sales up, orders soar
IDEX reported Q4 sales of $899M, up 4% reported and 1% organic, with record orders of $979M surging 20% on HST strength from AI data centers and semis. Adjusted EPS hit $2.10, up 3%, while full-year sales reached $3.5B and free cash flow $617M. Orders exploded. 2026 guides 1-2% organic sales growth, adjusted EPS $8.15-$8.35, but FMT/FSDP face demand weakness.
8-K
CFO appointed; CHRO departs
IDEX Corporation appointed Sean M. Gillen as SVP and CFO effective January 5, 2026, bringing expertise from AAR Corp. in financial performance and M&A; interim CFO Akhil Mahendra returns to corporate development. CHRO Melissa S. Flores resigned effective December 19, 2025, to pursue other opportunities. IDEX plans external HR hire focused on talent. Leadership refresh targets strategy execution.
8-K
IDEX Q3 sales hit record
IDEX Corporation reported third-quarter 2025 sales of $879 million, up 10% reported and 5% organically, fueled by the Mott acquisition and price gains, while orders hit a record $880 million, rising 13% reported and 7% organically. Adjusted diluted EPS climbed 7% to $2.03 amid higher interest from Mott debt, yet platform optimizations delivered $60+ million in annual savings. Full-year adjusted EPS guidance narrowed to $7.86-$7.91. Acquisitions like Micro-LAM for $80.7 million bolster growth, but macroeconomic uncertainty looms.
IPO
Website
Employees
Sector
Industry
DCI
Donaldson Company, Inc.
91.12-1.39
DOV
Dover Corporation
196.61-4.69
FLS
Flowserve Corporation
70.42-1.40
IR
Ingersoll Rand Inc.
79.61-2.02
IRIX
IRIDEX Corporation
1.00+0.02
ITT
ITT Inc.
175.05+1.00
ITW
Illinois Tool Works Inc.
250.66-8.00
NDSN
Nordson Corporation
236.37-1.42
RRX
Regal Rexnord Corporation
144.21-3.83
SXI
Standex International Corporati
228.24-2.35